$2.18
0.27% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US15117K1034
Symbol
CLLS
Sector
Industry

Cellectis SA Sponsored ADR Stock price

$2.18
-0.20 8.24% 1M
-0.49 18.20% 6M
-0.90 29.09% YTD
+0.58 36.50% 1Y
-11.33 83.83% 3Y
-8.17 78.90% 5Y
-37.12 94.44% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.01 0.27%
ISIN
US15117K1034
Symbol
CLLS
Sector
Industry

Key metrics

Market capitalization $157.89m
Enterprise Value $-4.73m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -0.36
P/S ratio (TTM) P/S ratio 12.12
P/B ratio (TTM) P/B ratio 1.48
Revenue growth (TTM) Revenue growth -21.33%
Revenue (TTM) Revenue $13.03m
EBIT (operating result TTM) EBIT $-101.30m
Free Cash Flow (TTM) Free Cash Flow $49.08m
Cash position $272.81m
EPS (TTM) EPS $-1.11
P/E forward negative
P/S forward 3.04
EV/Sales forward negative
Short interest 0.48%
Show more

Is Cellectis SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Cellectis SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cellectis SA Sponsored ADR forecast:

4x Buy
67%
2x Hold
33%

Analyst Opinions

6 Analysts have issued a Cellectis SA Sponsored ADR forecast:

Buy
67%
Hold
33%

Financial data from Cellectis SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
13 13
21% 21%
100%
- Direct Costs 19 19
4% 4%
148%
-6.24 -6.24
141% 141%
-48%
- Selling and Administrative Expenses - -
- Research and Development Expense 90 90
9% 9%
693%
-82 -82
5% 5%
-632%
- Depreciation and Amortization 19 19
-
145%
EBIT (Operating Income) EBIT -101 -101
6% 6%
-777%
Net Profit -80 -80
17% 17%
-614%

In millions USD.

Don't miss a Thing! We will send you all news about Cellectis SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cellectis SA Sponsored ADR Stock News

Neutral
GlobeNewsWire
24 days ago
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a scientific article in Science Advances suggesting that TALEN®-edited MUC1 CAR T-cells could be a potential treatment option for advance-s...
Positive
Seeking Alpha
28 days ago
Cellectis S.A. leverages its UCART platform and TALEN gene-editing technology to develop innovative, off-the-shelf CAR-T therapies for cancer treatment. UCART22, a key candidate in Cellectis's pipeline, shows promising efficacy and safety for ALL with CLLS52. The company's promising pipeline also includes UCART20x22 for NHL with a favorable safety profile.
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Molecular Therapy demonstrating TALEN®-mediated gene editing capabilities for design of SMART DUAL CAR T-cells, which efficien...
More Cellectis SA Sponsored ADR News

Company Profile

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Head office France
CEO André Choulika
Employees 221
Founded 1999
Website www.cellectis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today